554 related articles for article (PubMed ID: 33220249)
41. [Cardiovascular disease risk factors in patients with non-alcoholic fatty liver disease].
Novaković T; Inić Kostić B; Milinić S; Jovićević L; Dzeletović G
Med Pregl; 2013; 66(1-2):24-31. PubMed ID: 23534297
[TBL] [Abstract][Full Text] [Related]
42. Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome.
Lim S; Taskinen MR; Borén J
Obes Rev; 2019 Apr; 20(4):599-611. PubMed ID: 30589487
[TBL] [Abstract][Full Text] [Related]
43. Vascular Disease in Patients with Nonalcoholic Fatty Liver Disease.
Potze W; Siddiqui MS; Sanyal AJ
Semin Thromb Hemost; 2015 Jul; 41(5):488-93. PubMed ID: 26049073
[TBL] [Abstract][Full Text] [Related]
44. COVID-19, adaptative immune response and metabolic-associated liver disease.
Miele L; Napodano C; Cesario A; De Magistris A; Pocino K; Basile U; Rapaccini GL; Gasbarrini A; Grieco A
Liver Int; 2021 Nov; 41(11):2560-2577. PubMed ID: 34555255
[TBL] [Abstract][Full Text] [Related]
45. Non-alcoholic fatty pancreas disease.
Alempijevic T; Dragasevic S; Zec S; Popovic D; Milosavljevic T
Postgrad Med J; 2017 Apr; 93(1098):226-230. PubMed ID: 28069746
[TBL] [Abstract][Full Text] [Related]
46. Correlation between non-alcoholic fatty liver disease (NAFLD) and dyslipidemia in type 2 diabetes.
Krishan S
Diabetes Metab Syndr; 2016; 10(2 Suppl 1):S77-81. PubMed ID: 26810159
[TBL] [Abstract][Full Text] [Related]
47. Insulin-related biomarkers and their relationship with hepatic fibrosis risk in patients with psoriasis, metabolic syndrome and non-alcoholic fatty liver disease.
Kawada T
J Gastroenterol; 2013 May; 48(5):671-2. PubMed ID: 23440555
[No Abstract] [Full Text] [Related]
48. Nonalcoholic Fatty Liver Disease: Does This Metabolic Condition Have Brain Function Sequelae?
Beydoun MA; Canas JA
Neurology; 2022 Aug; 99(6):225-226. PubMed ID: 35940894
[No Abstract] [Full Text] [Related]
49. Nonalcoholic Fatty Pancreas Disease.
Shah N; Rocha JP; Bhutiani N; Endashaw O
Nutr Clin Pract; 2019 Oct; 34 Suppl 1():S49-S56. PubMed ID: 31535735
[TBL] [Abstract][Full Text] [Related]
50. Gender differences in the association of non-alcoholic fatty liver disease and metabolic syndrome with erosive oesophagitis: a cross-sectional study in a Taiwanese population.
Hung WC; Wu JS; Sun ZJ; Lu FH; Yang YC; Chang CJ
BMJ Open; 2016 Nov; 6(11):e013106. PubMed ID: 27852719
[TBL] [Abstract][Full Text] [Related]
51. Cardio-Metabolic Disorders in Non-Alcoholic Fatty Liver Disease.
El Hadi H; Di Vincenzo A; Vettor R; Rossato M
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31064058
[TBL] [Abstract][Full Text] [Related]
52. Prevalence and determinants of non-alcoholic fatty liver disease in lifelines: A large Dutch population cohort.
van den Berg EH; Amini M; Schreuder TC; Dullaart RP; Faber KN; Alizadeh BZ; Blokzijl H
PLoS One; 2017; 12(2):e0171502. PubMed ID: 28152105
[TBL] [Abstract][Full Text] [Related]
53. Macrophages and scavenger receptors in obesity-associated non-alcoholic liver fatty disease (NAFLD).
Kragh Petersen S; Bilkei-Gorzo O; Govaere O; Härtlova A
Scand J Immunol; 2020 Nov; 92(5):e12971. PubMed ID: 32892401
[TBL] [Abstract][Full Text] [Related]
54. Nonalcoholic fatty liver disease increases the risk of hepatocellular carcinoma in patients with alcohol-associated cirrhosis awaiting liver transplants.
Pais R; Lebray P; Rousseau G; Charlotte F; Esselma G; Savier E; Thabut D; Rudler M; Eyraud D; Vezinet C; Siksik JM; Vaillant JC; Hannoun L; Poynard T; Ratziu V
Clin Gastroenterol Hepatol; 2015 May; 13(5):992-9.e2. PubMed ID: 25459558
[TBL] [Abstract][Full Text] [Related]
55. Non-alcoholic fatty liver disease: A sign of systemic disease.
Reccia I; Kumar J; Akladios C; Virdis F; Pai M; Habib N; Spalding D
Metabolism; 2017 Jul; 72():94-108. PubMed ID: 28641788
[TBL] [Abstract][Full Text] [Related]
56. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups.
; Lonardo A; Bellentani S; Argo CK; Ballestri S; Byrne CD; Caldwell SH; Cortez-Pinto H; Grieco A; Machado MV; Miele L; Targher G
Dig Liver Dis; 2015 Dec; 47(12):997-1006. PubMed ID: 26454786
[TBL] [Abstract][Full Text] [Related]
57. The intertwisted correlations among non-alcoholic fatty liver disease, atherosclerosis, and metabolic syndrome.
Nakao H; Yoneda M
J Gastroenterol; 2009; 44(11):1162-4. PubMed ID: 19802516
[No Abstract] [Full Text] [Related]
58. Obstructive Sleep Apnea Syndrome and Metabolic Diseases.
Li M; Li X; Lu Y
Endocrinology; 2018 Jul; 159(7):2670-2675. PubMed ID: 29788220
[TBL] [Abstract][Full Text] [Related]
59. Emerging Targets to Relieve Fat Stress-Induced Liver Diseases: UDCA, Tocotrienol, ω-3 PUFAs, and IgY Targeted NPC1L1 Cholesterol Transporter.
Cha JY; Park JM; Lee HJ; Bae JS; Han YM; Oh BC; Ko KH; Hahm KB
Curr Pharm Des; 2017; 23(27):3941-3951. PubMed ID: 28714405
[TBL] [Abstract][Full Text] [Related]
60. The association between pancreas steatosis and metabolic syndrome: A systematic review and meta-analysis.
Bi Y; Wang JL; Li ML; Zhou J; Sun XL
Diabetes Metab Res Rev; 2019 Jul; 35(5):e3142. PubMed ID: 30767421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
